HER-2个导下胃肠肿瘤的治疗.pptxVIP

;Agenda;Agenda;Agenda;Agenda;Agenda;Please continue to the next chapter.;;The HER2 Receptor;Testing for HER2 Abnormalities;HER2 Testing in CRC;HER2 Testing in CRC;HER2 Testing in CRC;HER2 Testing in Gastric and GEJ Cancers;Mechanisms of Resistance to HER2-Targeted Therapies;Mechanisms of Resistance to HER2-Targeted Therapies;Mechanisms of Resistance to HER2-Targeted Therapies;Please continue on to the next chapter.;;HER2/ERBB2 Overexpression/Amplification in CRC;ERBB2 Amplification as a Predictive Biomarker;Current Use of HER2-Targeted Agents in CRC;HERACLES-A;HERACLES-A: Response Outcomes;MyPathway;MyPathway: Efficacy Outcomes;DESTINY-CRC01;DESTINY-CRC01: Response Outcomes (Primary Analysis);DESTINY-CRC01: Response Outcomes (Final Analysis);DESTINY-CRC01: Survival Outcomes (Final Analysis);MOUNTAINEER;Other Studies of HER2 Agents in CRC;Other Studies of HER2 Agents in CRC;Other Studies of HER2 Agents in CRC;Other Studies of HER2 Agents in CRC;Please continue to the next chapter.;;Role of HER2 in Gastric/GEJ Cancers;Heterogeneous HER2 Expression in Gastric Cancer;Current Use of HER2-Targeted Agents in Gastric/GEJ Cancers;ToGA;ToGA: Survival Outcomes;KEYNOTE-811;KEYNOTE-811: Response Outcomes;MAHOGANY;DESTINY-Gastric01;DESTINY-Gastric01: Response Outcomes (Primary Analysis);DESTINY-Gastric01: Survival Outcomes;DESTINY-Gastric03: Initial Data;Other Studies of HER2 Agents in CRC;Other Studies of HER2 Agents in CRC;Please continue to the next chapter.;;Cardiotoxicity;Interstitial Lung Disease or Pneumonitis;GI Toxicities;